STOCKHOLM, Sweden, April 25, 2003 (PRIMEZONE) -- Biora AB (publ):
1st Qtr 1st Qtr Full Year 2003 2002 2002 Net sales, SEK million 34.6 35.0 129.7 Operating result, SEK million 1.4 -1.0 -0.9 Net result, SEK million 1.4 -0.7 0.7
- On April 7, 2003, Straumann Holding AG announced a public offer to the shareholders and warrant holders of Biora AB. Biora's Board of Directors unanimously recommends that Biora shareholders accept the cash offer of SEK 17 per ordinary share.
- Sales during the first quarter 2003 amounted to SEK 34.6 million (compared to SEK 35.0 million for the first quarter 2002).
- Significant negative impact on sales during the first quarter 2003 due to the decline in the U.S. dollar exchange rate compared to the first quarter 2002.
- Net income during the first quarter 2003 was SEK 1.4 million (compared to a net loss of SEK 0.7 million for the first quarter 2002).
- Net change in cash for the first quarter 2003 was SEK -4.2 million (compared to SEK -3.5 million for the first quarter 2002).
Biora develops, manufactures and sells biotechnology-based products to dentists. Its principal product, Emdogain(R)Gel, which is approved for sale in Europe, North America and Japan among others, naturally regenerates the tooth-supporting structure that the tooth has lost due to periodontitis. Biora's shares are listed on the "O-list" of the Stockholm Stock Exchange in Sweden.
For further information, please contact: Svante Lundell, CFO and Investor Relations, Biora tel: +46 40-32 13 56 or +46 705 32 30 56 Donna Janson, President and CEO of Biora tel: +46 40 32 12 28 http://www.biora.com
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2003/04/25/20030425BIT00880/wkr0001.doc
The full report
http://www.waymaker.net/bitonline/2003/04/25/20030425BIT00880/wkr0002.pdf
The full report